You just read:

Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017

News provided by

Xencor, Inc.

Jun 16, 2017, 08:00 ET